Supplement-anticonvulsant interactions: what neurologists watch for

← Back to articles

Anti-seizure (antiepileptic) drugs are unusually unforgiving. A 30% drop in the drug's blood level can be the difference between staying seizure-free and having a breakthrough seizure; a 30% rise can tip into toxic side effects. Many of these drugs are broken down by the liver's drug-processing enzymes, travel through the blood stuck to blood proteins, and work only within a narrow dose range, so interactions that would be harmless with other medicines can matter here. Several common supplements can shift these blood levels — sometimes by a lot — and some can make seizures easier to trigger directly.

Why Anticonvulsants Are Interaction-Prone

Most major anticonvulsants are either hepatic enzyme inducers (phenytoin, carbamazepine, phenobarbital, primidone), inhibitors (valproate), or sensitive substrates (lamotrigine via glucuronidation, levetiracetam predominantly renal). Lamotrigine and valproate have especially complex interactions because of competition for glucuronidation and protein binding. The newer agents (lacosamide, eslicarbazepine, perampanel) have somewhat cleaner profiles but are not interaction-free. Because so many of these drugs run through the same CYP3A4 and UGT pathways that herbal products affect, the supplement aisle is a real source of risk.

St John's Wort: the Largest Single Concern

St John's wort is one of the most potent botanical inducers of CYP3A4 and CYP2C19 known, and it lowers plasma levels of many CYP3A4 substrates. For anticonvulsants the picture is drug-specific: dedicated human pharmacokinetic testing found that two weeks of St John's wort did not further induce the clearance of carbamazepine (itself already a strong auto-inducer), so not every pairing produces a measurable drop. But for substrates that are not maximally induced at baseline — and for the serotonergic burden St John's wort adds on top of mood-active anticonvulsants — neurologists routinely include it on the do-not-add list, and case reports describe loss of seizure control after patients started it for depression. The safest posture is to treat St John's wort as incompatible with an antiepileptic regimen.

Ginkgo biloba: Pro-Convulsant Risk

Ginkgo seeds contain 4'-O-methylpyridoxine (ginkgotoxin), a vitamin B6 antagonist that can lower the seizure threshold; in animal models ginkgotoxin reliably provokes seizure-like activity that is reversed by pyridoxal-5'-phosphate and standard antiepileptic drugs. Leaf extracts contain far less ginkgotoxin than the seeds, but case reports describe breakthrough seizures in patients on anticonvulsants who added ginkgo, and complementary-therapy reviews list it as a relative contraindication in epilepsy.

Evening Primrose, Borage, and Other GLA Sources

Evening primrose oil and borage oil are sometimes used for premenstrual symptoms and dermatologic complaints. Case reports describe a lowered seizure threshold, possibly through prostaglandin-metabolite effects. The mechanism is debated, but the signal has appeared in enough reports that some clinicians treat these gamma-linolenic-acid oils as caution items in epilepsy.

CBD and Cannabidiol Products

Prescription-grade cannabidiol (CBD) is approved as adjunctive therapy for Lennox-Gastaut and Dravet syndromes; in the pivotal randomized trial of CBD for Dravet syndrome, it reduced convulsive-seizure frequency more than placebo but also raised rates of diarrhea, somnolence, and abnormal liver-function tests. At therapeutic doses it raises serum levels of clobazam and interacts with valproate, and the combination of CBD plus valproate carried a hepatotoxicity signal requiring liver-enzyme monitoring. Over-the-counter CBD products are typically lower in dose but variable in purity and can produce similar interaction patterns without the oversight that comes with the prescription product.

Folic Acid: the Unrecognized Pillar

Many anticonvulsants — particularly the enzyme-inducing older agents — accelerate folate metabolism and produce relative folate deficiency. This is especially important in women of childbearing age because valproate and carbamazepine are associated with neural-tube defects, and periconceptional folic acid is recommended for women with epilepsy who may become pregnant. Case-control data show daily folic-acid supplementation is associated with lower neural-tube-defect risk in higher-risk pregnancies, including those exposed to antiepileptic drugs. The interaction here is the opposite of harmful — supplementation corrects a drug-induced deficit — but the dose and timing must be coordinated with the neurologist, and folic acid does not eliminate the need for diagnostic ultrasound.

Vitamin D and Bone Health

Long-term enzyme-inducing anticonvulsant therapy accelerates vitamin D metabolism, lowering serum 25-hydroxyvitamin D and contributing to reduced bone mineral density and fracture risk; reviews of bone health in epilepsy recommend vitamin D and calcium supplementation for patients on long-term therapy. This is not an interaction to avoid but one to actively manage, with periodic monitoring of vitamin D status and bone density in chronic users.

What Patients Should Disclose

Patients with epilepsy should give their neurologist a complete supplement list at every visit, including herbal teas, and should discuss any new product before starting it. Particular attention is needed for products marketed for "stress," "sleep," "mood," or "energy" — categories that disproportionately include CYP-active or CNS-active herbs such as St John's wort, ginkgo, and valerian-containing combinations. Therapeutic drug monitoring of serum anticonvulsant levels is the empirical way to detect an interaction; patients on tightly controlled regimens may benefit from a level check two to four weeks after any supplement change. The general rule is simple: on an antiepileptic regimen, do not self-initiate a supplement, and make sure the prescriber always knows exactly what you are taking.